What is AFFiRiS?
AFFiRiS is a specialized biopharmaceutical enterprise dedicated to the development of novel immunotherapies. At the core of its operations is the proprietary AFFITOME technology, which facilitates the creation of Specific Active Immunotherapies (SAIT). These therapies are designed to stimulate the immune system to effectively combat disease progression, with a primary focus on neurodegenerative disorders and hypercholesterolemia. By prioritizing patient quality of life and optimizing dosing regimens, the company occupies a distinct niche in the biotechnology landscape, aiming to solve significant unmet medical needs through scientific rigor and clinical innovation.
How much funding has AFFiRiS raised?
AFFiRiS has raised a total of $66.1M across 4 funding rounds:
Other Financing Round
$33.9M
Private Equity
$11.3M
Other Financing Round
$10M
Other Financing Round
$10.9M
Other Financing Round (2011): $33.9M with participation from MIG Capital
Private Equity (2016): $11.3M, investors not publicly disclosed
Other Financing Round (2016): $10M supported by FCPG Affi, Santo Holding, and MIG Capital
Other Financing Round (2017): $10.9M featuring MIG Capital
Key Investors in AFFiRiS
MIG Capital
MIG Capital is a Munich-based venture capital firm that primarily invests in innovative ideas across Europe, focusing on startups in the Life Sciences and Deep Tech sectors. The company aims to overcome boundaries and improve the world, placing founders at the center of their efforts.
Santo Holding
Santo Holding is a private investment firm with a strong focus on the pharmaceutical and biotechnology sectors, often supporting long-term medical research initiatives.
FCPG Affi
FCPG Affi is an investment vehicle participating in strategic funding rounds to support the advancement of clinical-stage biopharmaceutical technologies.
What's next for AFFiRiS?
With the recent influx of capital, AFFiRiS is well-positioned to accelerate its clinical development programs. The strategic focus will likely center on advancing its lead candidates through rigorous human trials, ensuring that the promise of its SAIT platform translates into tangible therapeutic outcomes. As the company moves deeper into its clinical-stage lifecycle, the emphasis will shift toward regulatory milestones and potential commercialization partnerships. Investors and industry observers will be closely monitoring the firm's ability to maintain its momentum in the competitive immunotherapy market, particularly as it seeks to validate its technology against some of the most challenging chronic diseases currently facing global healthcare systems.
See full AFFiRiS company page
